21 January 2025 - We have also recommended osimertinib for routine use on the NHS today.
The treatment landscape for lung cancer has changed considerably in the last decade, and survival rates have improved.
In the last 10 years NICE has made 48 positive recommendations for lung cancer treatments, 6 times more than in the previous decade.